CS261508B1 - Mouse Lymphocyte Lybridoma Producing Monoclonal Antibody for Specific Tumor Antigen of MSB1 - Google Patents
Mouse Lymphocyte Lybridoma Producing Monoclonal Antibody for Specific Tumor Antigen of MSB1 Download PDFInfo
- Publication number
- CS261508B1 CS261508B1 CS861488A CS148886A CS261508B1 CS 261508 B1 CS261508 B1 CS 261508B1 CS 861488 A CS861488 A CS 861488A CS 148886 A CS148886 A CS 148886A CS 261508 B1 CS261508 B1 CS 261508B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- msb1
- msb
- tumor antigen
- acid
- cell line
- Prior art date
Links
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Účelom riešenia je příprava izotypovo a idiotypovo homegénnej protilátky o vysokej čistotě. Uvedeného účelu sa dosiahne použitím myšieho lymíocytárneho hybridomu MSB—NTP—1, produkujúceho monoklonálnu protilátku rozpoznávajúcu specifický nádorový antigen lymfoblastoidnej bunkovej linie, označenej skratkou MSB1. Myší lymfocyíárny hybridům má použitie vo veterinárnej medicíně.The purpose of the solution is to prepare an isotype- and idiotype-homogeneous antibody of high purity. The stated purpose is achieved by using the mouse lymphocyte hybridoma MSB—NTP—1, producing a monoclonal antibody recognizing a specific tumor antigen of the lymphoblastoid cell line, denoted by the abbreviation MSB1. The mouse lymphocyte hybrid has applications in veterinary medicine.
Description
4 2815084 281508
Vynález sa týká myšieho lymfqjcyt^rij^hq ihybridómu produkujúqehf?] itrrbsokidnálnu’zprotilátku, rozpoznávajúcu špecif.ický nádo-rový antigén lymfoblastoidnéj bunkoVe]·' li-nie označenej skratkou MSB1.BACKGROUND OF THE INVENTION The present invention relates to a mouse lymphocytic hybridoma producing an antibody that recognizes a specific tumor antigen, lymphoblastoid cell, designated MSB1.
Doposial' sa protilátky proti lymfoblasto-idnej bunkovej linii MSB1, ktorá nesie nasvojom povrchu diagnostický antigén „MAT-SA“ připravovali tak, že sa pokusným zvie- ,rátám (králík, ovca] aplikovali živé MSB1buňky. VzhTadom na to, že nestačí jednadávka buniek pre vyvolanie dostatočne vy-sokej protilátkovej odpovede, je potřebnéich injikovať viackrát opakované v různýchdávkách a časových intervaloch. Sérum tak-to imunizovaných zvierat slúži ako zdrojprotilátek, najma pri diagnostickom vyšet-řovaní chovov hydiny. Zmienený postup i-munizácie má niekoíko nevýhod. Získávása heterogénna zmes protilátok, ktorýchrozloženie sa v organizme producenta mě-ní, je velmi různorodé, kvalitativně a kvan-titativné kolíše od jedného odběru po dru-hý a je neopakovatelné. Okrem toho sérumobsahuje hlavně·,·jiežiadúce protilátky proti .povrchovým antigénom, ktoré sa vyskytujúaj na normálnych buňkách. V důsledku toho je potřebné séra upra-vovat zložitými postupmi vysýtenia pomo-cou normálnych slezinových buniek tak, abysérum obsahovalo protilátky len proti spe-cifickému nádorovému antigénu. Touto ú-pravou dochádza k velkým stratám na sé-re a výraznému zníženiu titra specifickýchprotilátok. Pochopitelné proces vysýtenianie je možné standardizovat, v důsledkučoho sa i tak vysoká heterogenita konven-čných sér ešte prehíbi. Okrem toho využi-telnost takto připravených diagnostickýchsér je znížená aj tým, že ich specifické po-lyklonálne protilátky sú z hladiska inter-akcie s povrchovými buňkovými antigén-mi velmi různorodé. Navlac příprava do-statočného množstva lymfoblastoidných bu-niek MSB1 pre imunizačné účely je nároč-ná na technické vybavenie pracoviska, kva-lifikovaný personál a finančně prostriedky.Up to now, antibodies to the lymphoblastoid cell line MSB1, which carry the surface of the diagnostic antigen "MAT-SA", have been prepared by applying live MSB cells to the experimental animals (rabbit, sheep). For example, to induce a sufficiently high antibody response, it is necessary to inject multiple times at different dosages and intervals of time.The serum of such immunized animals serves as a source of antibodies, especially in the diagnostic examination of poultry breeding. the mixture of antibodies whose distribution in the producer is varied is very diverse, qualitatively and quantitatively varying from one sampling to the next and is unrepeatable, and in addition, the serum contains mainly desirable antibodies against the surface antigens that occur on normal cells sera can be treated by complex sputum clearance procedures so that the serum contains antibodies only against the specific tumor antigen. This effect leads to large losses in serum and a significant decrease in the specific antibody titer. An understandable process of satiety can be standardized, so that even the high heterogeneity of conventional sera is overwhelmed. Furthermore, the usefulness of the diagnostic reagents thus prepared is also reduced by the fact that their specific polyclonal antibodies are highly heterogeneous in terms of the interaction with surface cell antigens. In addition, preparation of a sufficient amount of lymphoblastoid cells MSB1 for immunization purposes is demanding in terms of workplace equipment, skilled personnel and financial means.
Hybridům MSB-NTP-1 bol připravený zná-mým spůsobom, klonováním skupiny hybri-dómov v mákkom agare, vzniklých fúzioubuniek myšej 2-am!no-hydroxy-8-azapurín(8-azaguanín) rezistentnej myelómovej li-nie označenej NSO a slezinových buniek in-brednej linie myší BALB/c, imunizovanýchlymfoblastoidnou buňkovou Jíniou MSB1 (G.Kůhler, C. Milstein, G. W. Butecher, J. C.Howard: Nátuře 286, 550 (1977]].MSB-NTP-1 hybrids were prepared in a manner known per se by cloning a hybridoma group in sputum agar, resulting in mouse 2-amino-hydroxy-8-azapurine (8-azaguanine) resistant NSO-spleen resistant spleen cells. BALB / c mice in the ancillary cell line, immunized with mephoblastoid cell lineage MSB1 (G. Khuhler, C. Milstein, GW Butecher, JCHoward: Nature 286, 550 (1977)].
Uvedené nevýhody v podstatnej miere od-straňuje vynález, ktorého podstata spočíváv myšom lymfocytárnom hybridóme MSB--NTP-1, produkujúcom monoklonálnu proti-látku podtriedy IgGl, kappa, rozpoznáva-júcu specifický nádorový antigén lymfob-lastoidnej bunkovej linie označenej skrat-kou MSB1. Tento hybridům je uložený voVirologickom ústave SAV, Mlýnská dolina1, 817 03 Bratislava. Výhodou hybridómu ^je, že produkuje izo-typovo homogéníuWprotilátku, tzv. meno-klonálnu protilátku, ktorá rozpoznává Spe-cifický; jjnádůřovy antigén lymfoblastoidnejbunkovej linie označenej skratkou MSB1 atým je ju možné použit na ídentifikáciu spe-cifického nádorového antigénu pri diferen-ciálnej diagnostike nádorových ochoreníhydiny. Jednobunkový lymfocytárny hybri-dům MSB-NTP-1 rastie in vivo v peritoneál-nej dutině BALB/c myší za súčasnej tvorbyascites. Rastie aj in vitro v kultivačných mé-diách vhodných pre živočišné buňky. Tak-tiež po zmrazení a uložení v tekutom dusí-ku a po opátovnom rozmražení si zachová-vá svoju schopnost produkovat monoklo-nálnu protilátku rozpoznávajúcu specifickýnádorový antigén lymfoblastoidnej bunko-vej linie označenej skratkou MSB1. Neob-sahuje na rozdiel od konvenčných aníisérnevhodné, nešpecifické, balastné protilátky. Příklad 1The above drawbacks are substantially obviated by the invention, which is based on the mouse lymphocyte hybridoma MSB-NTP-1, producing a monoclonal anti-substance subclass IgG1, kappa, recognizing the specific tumor antigen of the lymphoblastoid cell line designated MSB1. These hybrids are stored in the Virological Institute of the Slovak Academy of Sciences, Mlýnská dolina1, 817 03 Bratislava. An advantage of the hybridoma is that it produces an iso-homogeneous antibody, the so-called clonal antibody, which recognizes a specific one; The antigen of the lymphoblastoid cell line designated by the abbreviation MSB1 can be used to identify a specific tumor antigen in the differential diagnosis of tumor diseases. The single cell lymphocyte hybridoma MSB-NTP-1 grows in vivo in the peritoneal cavity of BALB / c mice with concomitant production of aspites. It also grows in vitro in culture cells suitable for animal cells. Also, after freezing and storage in liquid nitrogen and after re-thawing, it retains its ability to produce a monoclonal antibody recognizing a specific tumor antigen of the lymphoblastoid cell line designated MSB1. Unlike conventional anisotropic, non-specific, ballast antibodies, it does not. Example 1
Pre přípravu hybridnej bunkovej linie sapoužije 2.107 buniek myšej 2-amíno>-hyd-roxy-8-azapurín (8-azaguaninj rezistentnejbunkovej linie, ktorá sa pomocou 1 ml 50pere. hmot. polyetylénglykolu spoja s 1.108slezinových lymfoidných buniek myši imu-nizované]' 3.108 MSB1 lymfoblastoidnýchbuniek. V priebehu 14 dní vyrastú pod se-lektívnym tlakom kyseliny 4-amíno pteroyl-glutámovej (amínopterínu] hybridně buň-kové linie, ktoré produkujú monoklonálneprotilátky rozpoznávajúce specifický nádo-rový antigén lymfoblastoidnej bunkovej li-nie označenej skratkou MSB1. Tieto buňkysa potom klónujú tak, že sa zmieša 0,5 %hmot. agaru s 5 .10e až 10.106 myších sle-zinových buniek v médiu RPMI 1 640, ktoréobsahuje 100 mg. ml-1 tetrahydrátu dusičnatu vápe-natého, 2 000 mg . ml-1 D-glukózy, 100 mg. ml-1 heptahydrátu síranu horečna-tého, 400 mg . ml-1 chloridu draselného, 1512 mg.ml~J hydrogenfosforečnanu sod-ného, 6 000 mg . ml"1 monohydrátu dihydrogenfos-forečnanu sodného, 100 mg . ml"1 kyseliny 2-amíno-5-guanidíno-valérovej (arginínu), 50 mg. ml-1 kyseliny 2-amínosukcinamovej (asparagínu], 20 mg . ml 1 kyseliny 2-ainínojantárovej (ky-seliny asparágovej), s 2 S 1 a 3 50 mg.ml“1 kyseliny 3‘,3‘-ditiobis(2-aim'no-propánovej) (cystínu), 20 mg.ml“1 kyseliny 2-amínoglutárovej(kyseliny glutamovej), 300 mg. ml"1 kyseliny 2-amínoglutarámovej(glutamínu), 1 mg. ml-1 kyseliny 2-amínogIutaraminyl 2--merkaptopropionyl-aroínooctovej (gluta-tionu t. j. glutamínyl-cysteinyl-glycínu), 10 mg.ml“1 kyseliny amínooctovej (glycí-nu), 15 mg.ml“1 kyseliny -amíno-l-iroidaz:l-4--propiónovej (histidínu), 50 mg. ml“1 kyseliny 2-amíno-3-metylvalé-rovej (izoleucínu), 50 mg.ml“1 kyseliny 2-amíno-4-metylvaIé-rovej (leucínu), 40 mg .ml“1 kyseliny 2,6-diamínohexánovej(lyzínu), 15 mg.ml“1 kyseliny 2-amíno-4-(metyltio)-maslovej (metionínu), 15 mg .ml“1 kyseliny 2-amíno-3-fenylpropió-novej (fenylalanínu), 20 mg.ml“1 kyseliny 2-pyrolidínkarboxylo-vej (prolinu), 30 mg.ml“1 kyseliny 2-amíno-3-hydroxypro-plónovej (serínu), 20 mg.ml“1 kyseliny 2-amíno-3-hydroxy-maslovej (treonínu), 5 mg.ml“1 kyseliny 2-amíno-3-hydroxypro-piónovej (serínu), 20 mg.ml“1 kyseliny 2-amíno-3-hydroxy-maslovej (treonínu), 5 mg.ml“1 kyseliny 2-amíno-3-(3-indolylj-propiónovej (tryptofánu), 20 mg.ml“1 kyseliny 2-amíno-3-(4-hydroxy-fenyl) -propiónovej (týrozínu), 20 mg. ml“1 kyseliny 2-amíno-3-me tyl máslo-vé) (valínu), 0,2 mg.ml“1 kyseliny 5-(2-oxoimidazolidí-no/4,5-c/tioI-2-yl)pentánovej (biotínu), 0,005 mg.ml“1 kobalt[-(5,6-dimetylbenzimi-dazolyl) ]-kobalt-kyanokobamid vitamínuBl2> 0,250 mg.ml“1 D-N-(2,4-dihydroxy-3,3-diine- 8 tylbutyryl) -2-amínopropionát vápenatý (pantotenát vápenatý), 3 mg . ml"1 í-hydroxyetyltrimetylamóni-nn-chl orid (cbolínchlorid ], 1 mg.ml“1 kyseliny N-(2-aniíno-4-bydroxy-pteridín-6-./Imetyl) -p amínotenzoovej(kyseliny listové)), 35 mg . mV1 (1,2.3,5,/4,6/cyklobexóndex.d)(myonozítolu), 1 mg.ml“1 pyridin-3-karboxyaiuidu (ui?-o-tínamidu), 1 mg.ml"1 kyseliny 4-amínobenzoovej (ky-seliny p-amínobenzoovej), 1 mg .ml”1 3-hydroxy-4,5-bis(hydroxymetyl)--2-metylpyridinehloridu (pyridoxínchlori-du), 0,2 mg.ml“’ 7,8-dimetyl-10-(l‘-D-ribityl/izo-aloxažínu) (riboí lavinu), 1 mg . rol“1 3-(4-amíno-2-metyl-pyrimidyl-5--metyl )-5-( 2-hydr oxy etyl) -4-metyltiazolu(tiamínchloridu), 2 000 mg.ml'1 hydrogenuhličitanu sodnéhodoplnenom s 2 mmólmi kyseliny 2-amíno-glutarámovej (glutamínu), 5.10-5 mólov 2-merkaptoetanolu, 100 g.g.ml“1 O-L-2-deoxy-2-(metylanúno)--glukopyranozyl- (1-2)-0 -L-deoxy-3-C--f ormyllyxof uranozyl- (1-4-) -l,3-deoxy-l,3--diguanidoscyloinozytsulfátu (streptomy-cínsulfátu), 100 jednotiek na mílimeter kyseliny x-(N--ífinylacetaamidoj-penicilánovej (penici-línu G), 1 mmól kyseliny N-2-hydroxyetylpiperazín--N‘-2-etán sulfónovej (Hepesu) sa rozpustí v třikrát redestilovenej vodě adoplní třikrát redestilovanou vodou na ob-jem. 900 ml roztoku, ktorý sa doplní 100 mlnormálného ínaktivova n ého koňského sé-ra. Výsledné pH takto připraveného kultivač-ného média je 7,2. Po zatuhnutí agaru sa navrstvu 0,5 % hmot. agaru nanesie 100 byb-ridných buniek v 0,25 % hmot. agare. Po10 dňoch vyrastú kolonie, ktoré sa pomno-žia v médie RPMI 1 640 doplnenom s 2 mmól-mi kyseliny 2-amínoglutarámovej (glutamí-nu), 5.10“5 mólov 2-merkaptoetanolu, 100,ug . ml“1 O- -L-2-deoxy-2-(metylamíno)-glu-kopyranozyl-(l-2)-O- -L-deoxy-3-C-formyl-lyxofuranozyl- (1-4-1,3-deoxy-l,4-diguanido-scylolnozitsulfátu (streptomycínsulfátu), 1002.107 cells of mouse 2-amino-hydroxy-8-azapurine (8-azaguaninj resistant cell line, which are combined with 1 * 10 < 8 > -soluble lymphoid cells immunized with 1 ml of 50% by weight polyethylene glycol) are used to prepare the hybrid cell line. 3.108 MSB1 lymphoblastoid cells, within 14 days, under the selective pressure of 4-amino pteroyl-glutamic acid (aminopterin), hybrid cell lines that produce monoclonal antibodies recognizing the specific tumor antigen of lymphoblastoid cell line designated MSB1. then cloned by mixing 0.5% w / w agar with 5.10e to 10 x 10 6 mouse spleen cells in RPMI 640, containing 100 mg / ml of calcium nitrate tetrahydrate, 2000 mg / ml. 1 D-glucose, 100 mg / ml of magnesium sulfate heptahydrate, 400 mg / ml of potassium chloride, 1512 mg / ml of dibasic sodium phosphate, 6000 mg / ml of dihydrogen monohydrate sodium phosphate, 100 mg / ml of 2-amino-5-guanidino-valeric acid (arginine), 50 mg. ml-1 2-aminosuccinic acid (asparagine), 20 mg ml 1-2-amino succinic acid (aspartic acid), with 2 S 1 and 3 50 mg.ml "1 3 ', 3'-dithiobis (2- 2-aminoglutaric acid (glutamine), 300 mg / ml of 2-aminoglutaramic acid (glutamine), 1 mg / ml of 2-aminogutaraminyl 2 - mercaptopropionyl-aro-acetic acid (glutathione ie glutamyl-cysteinyl-glycine), 10 mg / ml aminoacetic acid (glycine), 15 mg / ml acid-amino-1-thiazole: 1-4 propionic (histidine), 50 mg / ml of 2-amino-3-methylvaleric acid (isoleucine), 50 mg / ml of 2-amino-4-methylvinyl (leucine), 40 mg / ml. 1-lysine acid, 15 mg / l of 2-amino-4- (methylthio) -butyric acid (methionine), 15 mg / ml 2-amino-3-phenylpropionic acid ( phenylalanine), 20 mg / ml 2-pyrrolidinecarboxylic acid (proline), 30 mg / ml 2-amino-3-hydroxyproic acid 2-amino-3-hydroxy-butyric acid (threonine), 5 mg / ml 2-amino-3-hydroxypropionic acid (serine), 20 mg / ml. Of 2-amino-3-hydroxy-butyric acid (threonine), 5 mg / ml of 2-amino-3- (3-indolyl) propionic acid (tryptophan), 20 mg / ml of 2-amino- 3- (4-hydroxy-phenyl) -propionic (tyrosine), 20 mg. ml of 2-amino-3-methylbutylic acid (valine), 0.2 mg / ml of 5- (2-oxoimidazolidino [4,5-c] thio-2-yl) acid pentanoic (biotin), 0.005 mg.ml “1 cobalt [- (5,6-dimethylbenzimidazol)] -cobalt-cyanocobamide vitaminBl2> 0,250 mg.ml“ 1 DN- (2,4-dihydroxy-3,3-diine) Calcium 8-butylbutyryl-2-amine propionate (calcium pantothenate), 3 mg. ml of "1'-hydroxyethyltrimethylammonium n-chloride (cboline chloride), 1 mg.ml" of N- (2-aniono-4-hydroxy-pteridine-6H-methyl) -piperidine-benzoic acid (folic acid), 35 mg mV1 (1.2.3.5, 4.6 / cyclobexondex.d) (myonosite), 1 mg / ml pyridine-3-carboxylate (.beta.-t-thiamine), 1 mg / ml. of 4-aminobenzoic acid (p-aminobenzoic acid), 1 mg .ml of 1-3-hydroxy-4,5-bis (hydroxymethyl) -2-methylpyridine chloride (pyridoxine chloride), 0.2 mg / ml. 7,8-dimethyl-10- (1'-D-ribityl / iso-aloxazine) (ribo avalanche), 1 mg. rol “1 3- (4-amino-2-methylpyrimidyl-5-methyl) -5- (2-hydroxyethyl) -4-methylthiazole (thiamine chloride), 2000 mg.mll of sodium bicarbonate with 2 2-amino-glutaramic acid (glutamine), 5.10-5 moles of 2-mercaptoethanol, 100 ggml "1 OL-2-deoxy-2- (methylanine) - glucopyranosyl- (1-2) -O-L-deoxy -3-C-furoyllyxof uranosyl- (1-4-) -1,3-deoxy-1,3-diguanidoscyloinozyme sulphate (streptomycin sulphate), 100 units per millimeter of x- (N-phenylacetaamido-penicillic acid ( penicillin G), 1 mmole of N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid (Hepesu) is dissolved in three times redistilled water, then taken up three times with redistilled water to a volume of 900 ml of solution, which is filled with 100 ml of normal The resulting pH of the culture medium thus prepared is 7.2, and after the agar has set, 100% by weight of the cells in 0.25% by weight of agar are applied to a layer of 0.5% by weight of agar. grow up colonies that are expand in RPMI 640 medium supplemented with 2 mmol of 2-aminoglutaramic acid (glutamine), 5 µl of 5 moles of 2-mercaptoethanol, 100 µg. ml of "O-L-2-deoxy-2- (methylamino) -glu-copyranosyl- (1-2) -O-L-deoxy-3-C-formyl-lyxofuranosyl- (1-4-1, 3-deoxy-1,4-diguanido-scylnolosine sulfate (streptomycin sulfate), 100
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS861488A CS261508B1 (en) | 1986-03-04 | 1986-03-04 | Mouse Lymphocyte Lybridoma Producing Monoclonal Antibody for Specific Tumor Antigen of MSB1 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS861488A CS261508B1 (en) | 1986-03-04 | 1986-03-04 | Mouse Lymphocyte Lybridoma Producing Monoclonal Antibody for Specific Tumor Antigen of MSB1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CS148886A1 CS148886A1 (en) | 1988-07-15 |
| CS261508B1 true CS261508B1 (en) | 1989-02-10 |
Family
ID=5349419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS861488A CS261508B1 (en) | 1986-03-04 | 1986-03-04 | Mouse Lymphocyte Lybridoma Producing Monoclonal Antibody for Specific Tumor Antigen of MSB1 |
Country Status (1)
| Country | Link |
|---|---|
| CS (1) | CS261508B1 (en) |
-
1986
- 1986-03-04 CS CS861488A patent/CS261508B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CS148886A1 (en) | 1988-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Greene et al. | Monoclonal antibodies to estrophilin: probes for the study of estrogen receptors. | |
| EP0176355A2 (en) | Antigen-independent immunoassay system | |
| JPH09294584A (en) | Monoclonal antibody against human tumor necrosis factor | |
| CA1225608A (en) | Monoclonal antibody to cardiac myosin heavy chain | |
| CS261508B1 (en) | Mouse Lymphocyte Lybridoma Producing Monoclonal Antibody for Specific Tumor Antigen of MSB1 | |
| Hadas et al. | Production of monoclonal antibodies: The effect of hybridoma concentration on the yield of antibody-producing clones | |
| JPH02486A (en) | Monoclonal antibody capable of recognizing free n-acetylneuraminic acid | |
| US4628032A (en) | Monoclonal antibody specific for a mammary tumor cytoplasmic antigen | |
| CS259233B1 (en) | Mouse Lymphocytes Hybridoma Producing Monoclonal Antibody Against MSBI Eymphoblastoid Cell Line | |
| CS259232B1 (en) | Myoma lymphocyte hybridoma producing a monoclonal antibody against poultry lymphocyte surface antigens | |
| Mochizuki et al. | Enhanced production of human monoclonal antibodies by the use of fructose in serum-free hybridoma culture media | |
| DiPauli et al. | A hybridoma secreting IgM anti-Iglb allotype | |
| CS260264B1 (en) | Mouse lymphocyte hybridoma producing monoclonal antibodies neutralizing Newcastle disease virus | |
| JPH0789998A (en) | Anti-microcystin monoclonal antibody and hybridoma producing the same | |
| CS259231B1 (en) | Mice lymphocytes hybridoma producing monoclonal antibody inhibiting Newcastle disease virus hemagglutination activity | |
| CS259230B1 (en) | Murine hybridoma producing monoclonal antibodies against Newcastle disease virus | |
| US5352584A (en) | Monoclonal antibodies which bind (E)-5- (2-bromovinyl)-arabinofuranosyluracil and diagnostic methods based thereon | |
| RU2049817C1 (en) | Strain of hybrid cultured murine cells mus musculus l used for preparing monoclonal antibodies to phenobarbital | |
| RU2059720C1 (en) | Strain of hybrid cultured murine cells mus musculus l used for preparing monoclonal antibodies to the human thyrotropic hormone | |
| KR920001376B1 (en) | Monoclonal antibody for human chorionic gonadotropin | |
| CS235850B1 (en) | Mouse lymphocyte hybridoma producing anti-human -transferrin antibody | |
| CS276203B6 (en) | Mouse hybridoma IFNA2-N10 producing monoclonal antibody binding human interferon alpha 2 | |
| RU2059721C1 (en) | Strain of hybrid cultured murine cells mus musculus l used for preparing monoclonal antibodies to the human thyrotropic hormone | |
| SU1721089A1 (en) | Strain of hybrid cultured mammalian mus musculus l - a producer of monoclonal antibody to glutamate receptors of human brain | |
| CS243652B1 (en) | Mouse lyaphocyte hybrid · IMG CZAS HP-03 |